利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

36 条记录 (耗时 0.034 秒)

    Anti-IL2 antibodies
    2.
    发明授权
    Anti-IL2 antibodies 有权
    抗IL2抗体

    公开(公告)号：US07964707B2

    公开(公告)日：2011-06-21

    申请号：US11916017

    申请日：2006-05-31

    申请人： Patrick Bäuerle ,  John Lumsden ,  Stefan Pflanz ,  Tobias Raum ,  Jörg Volkland

    发明人： Patrick Bäuerle ,  John Lumsden ,  Stefan Pflanz ,  Tobias Raum ,  Jörg Volkland

    IPC分类号： C12P21/08 ,  C07K16/00 ,  A61K39/00 ,  A61K39/395

    CPC分类号： C07K14/55 ,  C07K16/246 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76

    摘要： The invention relates to a humanized monoclonal antibody or fragment thereof which specifically binds to human interlukin-2 (IL2), whereby said humanized monoclonal antibody neutralizes the activity of human IL2 by binding to the human IL2 prior to, during, and/or subsequent to the binding of the human IL2 to the human IL2-receptor, and wherein the light chain variable region of the humanized monoclonal antibody comprises in its second framework region the contiguous amino acid sequence KAPKA at amino acid positions 42-46.

    摘要翻译： 本发明涉及与人白细胞介素-2（IL2）特异性结合的人源化单克隆抗体或其片段，其中所述人源化单克隆抗体在其之前，期间和/或之后通过与人IL2结合而中和人IL2的活性 人IL2与人IL2受体的结合，并且其中人源化单克隆抗体的轻链可变区在其第二框架区域中包含氨基酸位置42-46处的连续氨基酸序列KAPKA。

    Composition comprising cross-species-specific antibodies and uses thereof
    6.
    发明授权
    Composition comprising cross-species-specific antibodies and uses thereof 有权
    包含交叉物种特异性抗体的组合物及其用途

    公开(公告)号：US08236308B2

    公开(公告)日：2012-08-07

    申请号：US12083351

    申请日：2006-10-10

    申请人： Roman Kischel ,  Tobias Raum ,  Bernd Schlereth ,  Doris Rau ,  Ronny Cierpka ,  Peter Kufer

    发明人： Roman Kischel ,  Tobias Raum ,  Bernd Schlereth ,  Doris Rau ,  Ronny Cierpka ,  Peter Kufer

    IPC分类号： A61K39/395

    CPC分类号： A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/40 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/622

    摘要： The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of said bispecific anti-bodies exhibiting cross-species specificity. The present invention also relates to methods of measuring the biological activity and/or efficacy of such bispecific antibodies exhibiting cross-species specificity. In addition, the present invention relates to pharmaceutical compositions comprising bispecific single chain antibodies exhibiting cross-species specificity and to methods for the preparation of pharmaceutical compositions comprising said bispecific single chain antibodies exhibiting cross-species specificity for the treatment of diseases.

    摘要翻译： 本发明涉及显示跨物种特异性的双特异性抗体用于评估其在非人物种和人中的体内安全性和/或其活性和/或药代动力学特征的用途。 本发明还涉及用于评估展示跨物种特异性的所述双特异性抗体的体内安全性和/或活性和/或药代动力学特征的方法。 本发明还涉及测量显示跨物种特异性的这种双特异性抗体的生物活性和/或功效的方法。 此外，本发明涉及包含显示跨物种特异性的双特异性单链抗体的药物组合物和用于制备药物组合物的方法，所述药物组合物包含显示针对疾病治疗疾病的跨物种特异性的所述双特异性单链抗体。

    CROSS-SPECIES-SPECIFIC SINGLE DOMAIN BISPECIFIC SINGLE CHAIN ANTIBODY
    7.
    发明申请
    CROSS-SPECIES-SPECIFIC SINGLE DOMAIN BISPECIFIC SINGLE CHAIN ANTIBODY 审中-公开
    跨物种特异性单链单链单链抗体

    公开(公告)号：US20110275787A1

    公开(公告)日：2011-11-10

    申请号：US13122280

    申请日：2009-10-01

    申请人： Peter Kufer ,  Tobias Raum

    发明人： Peter Kufer ,  Tobias Raum

    IPC分类号： C07K16/18 ,  C07K14/435

    CPC分类号： C07K16/2863 ,  C07K16/2803 ,  C07K16/2878 ,  C07K16/2884 ,  C07K2317/31 ,  C07K2317/34

    摘要： The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain consisting of one antibody variable domain capable of binding to an epitope of the human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention further relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3ε (epsilon) chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain consisting of one antibody variable domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.

    摘要翻译： 本发明涉及双特异性单链抗体分子，其包含由能够结合人和非黑猩猩灵长类CD3ε链的表位的一个抗体可变结构域组成的第一结合结构域，其中所述表位是氨基酸序列的一部分 包括在由SEQ ID NOs组成的组中。 2,4,6和8以及能够结合人和非黑猩猩灵长类动物靶标抗原的表位的第二结合结构域。 本发明还涉及双特异性单链抗体分子，其包含能够结合人和非黑猩猩灵长类CD3抗原表位的第一结合结构域; （ε）链，其中所述表位是包含在SEQ ID NO中的氨基酸序列的一部分。 2,4,6和8以及由能够与人的表位结合的一个抗体可变结构域和非黑猩猩灵长类动物靶标抗原组成的第二结合结构域。 本发明还提供了编码所述双特异性单链抗体分子以及载体和宿主细胞的核酸及其生产方法。 本发明还涉及包含所述双特异性单链抗体分子的药物组合物和所述双特异性单链抗体分子的医学应用。

    Method of identifying binding site domains that retain the capacity of binding to an epitope
    8.
    发明授权
    Method of identifying binding site domains that retain the capacity of binding to an epitope 有权
    鉴定保留与表位结合的能力的结合位点结构域的方法

    公开(公告)号：US07435549B1

    公开(公告)日：2008-10-14

    申请号：US09554465

    申请日：1998-11-16

    申请人： Peter Kufer ,  Tobias Raum ,  Katrin Borschert ,  Florian Zettl ,  Ralf Lutterbuse

    发明人： Peter Kufer ,  Tobias Raum ,  Katrin Borschert ,  Florian Zettl ,  Ralf Lutterbuse

    IPC分类号： G01N33/53

    CPC分类号： C40B40/02 ,  A61K38/00 ,  C07K14/70525 ,  C07K14/70528 ,  C07K14/70532 ,  C07K16/3046 ,  C07K2319/00 ,  C12N15/1037

    摘要： The present invention relates to a method of identifying binding site domains that retain the capacity of binding to an epitope when positioned C-terminal of at least one further domain in a recombinant bi- or multivalent polypeptide. The present invention further relates to a kit comprising components such as panels of recombinant vectors of bacterial libraries transfected with a panel of recombinant vectors which is useful in carrying out the method of the invention. Furthermore, binding site domains and fusion proteins obtainable by the method of the invention as well as antibody-like molecules comprising such domains and proteins are described. Furthermore, pharmaceutical and diagnostic compositions containing the above-described fusion proteins and polypeptides are provided.

    摘要翻译： 本发明涉及一种鉴定结合位点结构域的方法，当定位在重组双或多价多肽中的至少另一个结构域的C-末端时，其保留与表位结合的能力。 本发明还涉及一种试剂盒，其包含诸如用于实施本发明的方法的重组载体的一组重组载体转染的细菌文库的重组载体的片段的组分。 此外，描述了可通过本发明的方法获得的结合位点结构域和融合蛋白以及包含这种结构域和蛋白质的抗体样分子。 此外，提供含有上述融合蛋白和多肽的药物和诊断组合物。

    Cross-species-specific single domain bispecific single chain antibody
    9.
    发明授权
    Cross-species-specific single domain bispecific single chain antibody 有权

    公开(公告)号：US10981998B2

    公开(公告)日：2021-04-20

    申请号：US13122280

    申请日：2009-10-01

    申请人： Peter Kufer ,  Tobias Raum ,  Roman Kischel ,  Ralf Lutterbüse ,  Patrick Hoffman ,  Matthias Klinger ,  Doris Rau ,  Susanne Mangold

    发明人： Peter Kufer ,  Tobias Raum ,  Roman Kischel ,  Ralf Lutterbüse ,  Patrick Hoffman ,  Matthias Klinger ,  Doris Rau ,  Susanne Mangold

    IPC分类号： C07K16/28

    摘要： The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain consisting of one antibody variable domain capable of binding to an epitope of the human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention further relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3ϵ (epsilon) chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain consisting of one antibody variable domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.